ARON 3D_Transparent

Publications

All our publications
Fc8 3lWCRLqx7XOiJKnILg

Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Massari F, et al.
Eur Urol Oncol.
2024
Progetto senza titolo

Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)

Fiala O, et al.
Target Oncol.
2024
ptEvy sPSu Jul tdAzoqA

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Incorvaia L, et al.
Cancer Immunol Immunother.
2024
1733375817474

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).

Ciccarese C, et al.
Int J Cancer.
2024
9YIYKy5dR5CW5VFojEs66Q

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

Santini D, et al.
Target Oncol.
2024
1733809351923

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

Santoni M, et al.
Cancer Immunol Immunother.
2023

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.